PTC Therapeutics agrees to buy Sangamo's ST-920 Fabry gene therapy for $111 million upfront
PTC Therapeutics entered an asset purchase agreement on August 25, 2026 to acquire ST-920, an AAV gene therapy candidate for Fabry disease, from bankrupt Sangamo Therapeutics. The deal carries a $111 million upfront payment plus up to $100 million in contingent milestones tied to FDA approval, and closing requires Bankruptcy Court approval, which is scheduled for a hearing on September 10, 2026.
Key points
- Upfront payment of $111 million, plus up to $100 million in contingent milestones ($80 million on accelerated approval and $20 million on full approval)
- Acquisition is subject to Bankruptcy Court approval (hearing scheduled September 10, 2026) and Hart-Scott-Rodino waiting period expiration
- Either party may terminate if closing has not occurred by October 15, 2026, subject to specified exceptions
- Representations and warranties do not survive closing and there is no indemnification for breaches
The filing
Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.